Reported Earnings • Apr 29
Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022) Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022). Reported Earnings • Jan 27
Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022) Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Aug 03
Canntab Therapeutics Limited Announces Chief Executive Office Changes Canntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Feb 12
Co-Founder recently bought CA$226k worth of stock On the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares. Duyuru • Feb 03
Canntab Therapeutics Limited announced that it has received CAD 1.312 million in funding Canntab Therapeutics Limited announced a non-brokered private placement of secured convertible debentures for gross proceeds of CAD 1,312,000 on February 1, 2022. The convertible debentures are convertible into common shares at a conversion price of CAD 0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the transaction, the company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events. The company also has the right to force the conversion of all of the principal amount of the then outstanding convertible debentures at the conversion price upon giving the Debenture holders not less than 30 days advance written notice, should the volume weighted average trading price of the shares on the Canadian Securities Exchange be greater than CAD 1.05 per share for the preceding 15 consecutive trading days. The convertible debentures shall bear interest at a rate of 10% per annum from the closing date, paid upfront in cash for the initial six months, thereafter payable quarterly in cash on the last business day of each calendar quarter. Any accrued but unpaid interest is convertible into shares, at the option of the holder at the conversion price at any time following the closing date. The company has also issued one Share purchase warrants for each share underlying the convertible debenture purchased. The warrants are exercisable for a period of three years from issuance into shares of the company with each warrant entitling the holder thereof to acquire one share at an exercise price of CAD 0.90 per share. There were no broker warrants issued or commission paid in connection to the offering. All of the securities issued pursuant to the transaction are subject to a statutory hold period of four months and one day from the closing date of the transaction. Duyuru • Jan 22
Canntab Therapeutics Limited Officially Launches its Online E-Commerce Platform Canntab Therapeutics Limited announced the official launch of its online e-commerce platform. The E-Commerce platform and web site provides Canadians with an opportunity to source true medical THC and CBD in a pharmaceutical grade hard tablet. The Canntab tablet provides patients with many added benefits including ease of use, efficacy, exact dosage, and bioavailability. Canntab is now able to script patients directly online, take in existing or new prescriptions from Doctors or even share a prescription with another LP. Canntab and its patented formulations is the only provider THC and CBD in hard tablet in Canada. Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the full commercialization of its brand and products. The recently announced OCS initial shipment and Australian 2nd shipment are just 2 examples of what is expected to be numerous developments in the very near future. In addition, affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend or prescribe product and be compensated for doing so. Recent Insider Transactions • Oct 03
Co-Founder recently bought CA$95k worth of stock On the 1st of October, Richard Goldstein bought around 135k shares on-market at roughly CA$0.70 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$339k worth in shares. Recent Insider Transactions Derivative • Jun 11
Co-Founder exercised options to buy CA$310k worth of stock. On the 7th of June, Richard Goldstein exercised options to buy 320k shares at a strike price of around CA$0.75, costing a total of CA$240k. This transaction amounted to 65% of their direct individual holding at the time of the trade. Since December 2020, Richard's direct individual holding has increased from 39.19k shares to 464.59k. Company insiders have collectively bought CA$525k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions • May 08
Co-Founder recently bought CA$60k worth of stock On the 5th of May, Richard Goldstein bought around 60k shares on-market at roughly CA$1.00 per share. In the last 3 months, they made an even bigger purchase worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$222k worth in shares. Recent Insider Transactions • Apr 28
Co-Founder recently bought CA$100k worth of stock On the 23rd of April, Richard Goldstein bought around 100k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$162k worth in shares. Duyuru • Apr 01
Canntab Receives Export License Approval from Health Canada Canntab Therapeutics Limited announced that Health Canada has granted the company an Export License. Duyuru • Mar 11
Canntab Therapeutics Limited Receives $400K Purchase Order in Australia Canntab Therapeutics Limited announced that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global"). The initial purchase order includes 6 sku's comprised of 2.5mg THC, 5mg THC, 12.5mg CBD, 25mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. Cann Global has already received its import license from the Australian Government Department of Health while Canntab is waiting for an Export License approval from Health Canada to fulfil and ship the order. The products ordered by Cann Global will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals. Canntab will update its shareholders as soon as its Export License has been approved. Is New 90 Day High Low • Feb 10
New 90-day high: CA$0.95 The company is up 36% from its price of CA$0.70 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period. Is New 90 Day High Low • Dec 09
New 90-day high: CA$0.76 The company is up 21% from its price of CA$0.63 on 09 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 53% over the same period. Duyuru • Dec 03
Canntab Therapeutics Limited Begins Delivery of Tablets to MediPharm Canntab Therapeutics Limited announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. Further to Canntab's announcement dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020. Duyuru • Nov 18
Canntab Therapeutics Limited Announces End of Supply and Distribution Agreements with Exactus Canntab Therapeutics Limited announced that Canntab and Exactus, Inc. have blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis. During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved. Duyuru • Nov 07
Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021 Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021. Duyuru • Oct 20
Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. On July 15, 2020, 200,000 common shares were issued to CMAX as a deposit on this transaction. The transaction is subject to customary closing conditions. The transaction has been approved by the independent Director of Canntab Therapeutics.
Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. on October 19, 2020. Duyuru • Oct 01
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt Canntab Therapeutics Limited filed its Annual on Sep 28, 2020 for the period ending May 31, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Sep 30
Full year earnings released - CA$0.10 loss per share Over the last 12 months the company has reported total losses of CA$2.61m, with losses widening by 6.0% from the prior year. Duyuru • Aug 22
Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million. Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. The transaction is subject to customary closing conditions. The transaction has been approved by the independent director of Canntab Therapeutics. Duyuru • Aug 20
Canntab Therapeutics Limited Announces Appointment of Larry Latowsky as CEO Canntab Therapeutics Limited announced that it has appointed Larry Latowsky as CEO effective immediately. Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the company and accordingly the board of directors decided to appoint Larry as CEO. 
